Zurich-Schlieren, Switzerland, 2 November 2023
We are pleased to announce that TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with partners from Yonsei University and Juvic Inc. in South Korea. The project aims to develop new technologies for the treatment of systemic sclerosis. We thank Innosuisse and the Korea Institute for Advancement of Technology (KIAT) for their support.
The Board of Directors of Topadur Pharma AG announces that Pascal Brenneisen will leave his position as CEO
Read moreTOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.
Read moreDiabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.
Read more